Drug intelligence / Profile preview

Xalix

Development stage: Unknown
Lead developer: Cintex Services
Modality: Small Molecules
Administration: Topical

Overview

Xalix is a topical prescription medication containing a high concentration (28%) of salicylic acid, manufactured for Cintex Services. It is specifically indicated for the treatment and removal of common warts and plantar warts. The drug functions as a keratolytic agent, which promotes the shedding of hyperkeratotic skin by dissolving the intercellular substance in the stratum corneum. This mechanical removal of epidermal cells helps eliminate tissue infected with wart viruses. Xalix is formulated in a polyacrylic, film-forming solution that adheres to the wart, providing a protective cover and localized treatment without the necessity of a bandage.

Brand names: XalixXalix Solution
Other names: salicylic acid 28%

Beyond the preview

Go deeper on Xalix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xalix.

Explore the full profile